Claritev Releases 2024 Corporate Responsibility Report
The 2024 report showcases the Company's strategic momentum in advancing its sustainability priorities during a pivotal year of transformation. The report emphasizes Claritev's continued focus on managing, tracking and disclosing its social and environmental performance, reinforcing its commitment to accountability and responsible growth.
'I've never been more excited about the opportunity ahead—to reshape healthcare through technology, data and insights that drive affordability, transparency and quality across the healthcare ecosystem,' said Travis Dalton, Chairman, and CEO of Claritev.
Dalton continued, 'I'm especially proud of our efforts to drive greater access and equity in healthcare. Our partnership with the National Rural Health Association helps extend the reach of our technology and data science capabilities to underserved communities.'
The report outlines Claritev's progress across key corporate responsibility priorities, including access to healthcare, data privacy and security, people strategy, ethics and transparency, and sustainable operations. Notable 2024 highlights include:
Completing our third greenhouse gas inventory covering Scope 1 and 2 emissions, reinforcing our commitment to transparency;
Reducing our carbon footprint by migrating to Oracle Cloud Infrastructure, with a target of 100% cloud storage by the end of 2025;
Enhancing our talent strategy with a new performance enablement model, 100% paid parental leave, and the appointment of a Director of Employee Engagement; and
Earning multiple workplace recognitions, including Fortune Best Workplace in Health Care™, Best Workplace in New York™, and Great Place to Work® Certification™ for the third consecutive year.
The full report is available on Claritev's website at the following link: https://www.claritev.com/corporate-responsibility/
About Claritev
Claritev, formerly known as MultiPlan, is a healthcare technology, data and insights company focused on delivering affordability, transparency and quality. Led by a team of deeply experienced associates, data scientists and innovators, Claritev provides cutting-edge solutions and services fueled by multiple data sources and over 40 years of claims repricing experience. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design. By focusing on purpose-built solutions that support all key players – including payors, employers, patients, providers and third parties – Claritev aims to make healthcare more accessible and affordable for all. For more information, visit claritev.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
3 Dividend Stocks to Hold for the Next 20 Years
Key Points General Mills is offering a historically high yield backed by a powerful and diversified food business. PepsiCo is a Dividend King with a high yield and iconic global brands. Hershey makes an affordable luxury that people will be willing to pay up for. 10 stocks we like better than PepsiCo › Remember one thing when you consider consumer staples makers: You "need" the products they sell. That's particularly true when it comes to food-focused consumer staples companies like General Mills (NYSE: GIS), PepsiCo (NASDAQ: PEP), and Hershey (NYSE: HSY). Here's why each one of these dividend stocks is worth buying and holding for 20 years, or more, right now. 1. General Mills is shifting with the times General Mills makes food products like cereal, snack bars, pet food, and baking products. It owns a collection of brand names that you likely know well, including Blue Buffalo and Cheerios. The brands and products it sells are staples in grocery stores and in consumer cupboards. It's highly unlikely that General Mills will suddenly go out of business anytime soon. That said, right now the company is facing some headwinds. Consumer buying habits are shifting, and some buyers are pulling back on spending. That has left General Mills' financial results weak. Sales and earnings fell year over year in the fourth quarter of fiscal 2025. The company's fiscal 2026 outlook was a bit weak, too. But management is doing what it can to adjust, including changing formulations to match current trends, adjusting its brand and product portfolio, and trying to keep a lid on costs. These are the right moves and, in time, they will likely lead to General Mills getting back on track. It always has in the past. While General Mills' stock is out of favor, you can buy it at an attractive 4.8% yield. That's near the highest levels in the company's history. If you like income and think long term, General Mills should probably be on your buy list today. 2. PepsiCo has industry-leading brands General Mills is a good company with industry-leading brands, but PepsiCo's brands stand out even more. It's the No. 2 beverage company and the No. 1 salty snack maker. It also makes packaged food products that compete with companies like General Mills. The problem for PepsiCo is that customer tastes are shifting, and it is out of step with its customers. The company is working on the issue -- it recently bought a Mexican-American food business and a probiotic beverage company. Both are more in line with current trends. Sure, PepsiCo's recent financial results aren't that great, and they lag those of its closest peers. It's OK -- that happens even to well-run businesses. PepsiCo didn't achieve Dividend King status by accident, and it has muddled through hard times before. It's highly likely that it will do so again. In the meantime, you can collect a historically high 3.9% dividend yield. If the dividend history here is any guide, you'll end up a long-term winner if you're willing to step in while the rest of Wall Street is selling. 3. Hershey's cocoa problem makes it hard to love Hershey is the most difficult story to appreciate here for two reasons. First, while it makes food, the most important product it sells is chocolate. That's not a necessity, even though people love the affordable indulgence. Second, the biggest headwind for the business is a shocking rise in the price of cocoa, a key ingredient in chocolate. Cocoa comes from trees, so it could take some time before high prices lead to changes in the industry. That's why investors have sold Hershey stock hard, leading to a historically high 2.9% dividend yield. Just how bad is it? Despite increasing prices and the expectation of sales growth in 2025, Hershey is projecting rising costs to lead to a roughly mid-30% drop in earnings in 2025. And given the nature of cocoa, the pain could linger for a bit. There's a good reason why investors are negative on the stock. But if you can stomach some near-term uncertainty, the long-term picture is likely to be continued and growing demand for the affordable luxuries that Hershey sells. You need and want what they make It is hard to suggest that chocolate, soda, or cereal are life necessities. You can certainly eat and drink other things. But these consumer staples giants have long delivered the food items that people want to buy. That will be just as true in one year as it is in 10 years or 20 years. The headwinds they face today aren't likely to change anything about the nature of these businesses, even if the companies do need to adjust to better align with current trends. The truth is that they've all done that many times before. Given the historically high yields on offer from General Mills, PepsiCo, and Hershey, buying and holding for decades is probably a good call for even the most conservative dividend investors today. Do the experts think PepsiCo is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did PepsiCo make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,036% vs. just 181% for the S&P — that is beating the market by 855.09%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Reuben Gregg Brewer has positions in General Mills, Hershey, and PepsiCo. The Motley Fool has positions in and recommends Hershey. The Motley Fool has a disclosure policy. 3 Dividend Stocks to Hold for the Next 20 Years was originally published by The Motley Fool
Yahoo
19 minutes ago
- Yahoo
Why AbbVie Stock Flew Higher on Friday
Key Points A trio of analysts raised their price targets on the pharmaceutical sector mainstay. This came a day after it published second-quarter results. 10 stocks we like better than AbbVie › A bellwether stock in the lately rather up-and-down pharmaceutical sector, AbbVie (NYSE: ABBV) finished the trading week in style. The company's shares closed more than 3% higher in price thanks in no small part to a clutch of post-earnings analyst price-target increases. With that performance, Abbvie crushed the S&P 500 index, which dived by 1.6% on the day. A bullish stampede As typically happens when a publicly traded company posts better-than-expected quarterly results, those pundits made the positive changes a day after AbbVie published its estimates-besting second-quarter figures. None of the price-target hikes were particularly dramatic, but since they came from analysts already bullish on AbbVie, they boosted sentiment on the stock. Morgan Stanley's Terrance Flynn now feels the shares are worth $255 apiece, up from his previous level of $250. His peers Gary Nachman at Raymond James and Guggenheim's Vamil Divan also upped their fair value assessments. In the former's case, he added $9 per share for a new price target of $236, while the latter increased his to $227 from $216. All three analysts maintained their equivalent of a buy recommendation on the stock. Blockbuster success Divan's note detailing his price-target change indicated the general tone of those modifications. According to reports, the pundit expressed admiration for the company's performance, singling out the growth in sales of certain blockbuster drugs, notably Skyrizi. Divan pointed out that much of this improvement was due to volume growth, meaning demand remains strong for such products. Should you buy stock in AbbVie right now? Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie. The Motley Fool has a disclosure policy. Why AbbVie Stock Flew Higher on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Why ChargePoint Stock Slumped This Week
Key Points It pulled the lever on a quite unpopular piece of financial engineering. At least the move will keep it in compliance with listing requirements. 10 stocks we like better than ChargePoint › It's safe to say that almost no investor likes it when one of their investments pulls off a reverse stock split. For very good reasons, this is generally seen as a desperate attempt to remain in compliance with the minimum share price listing requirements imposed by U.S. exchanges. So, it wasn't shocking at all that ChargePoint Holdings (NYSE: CHPT) took a real hit to its stock price largely because of the move -- which actually obscured more than one positive news item about the company. According to data compiled by S&P Global Market Intelligence, ChargePoint's share price fell by more than 22% over the course of the trading week. Reversal of fortune ChargePoint ripped the bandage off on Wednesday, formally splitting its stock at a ratio of 1-for-20. It's important to note here that no stock split, reverse or otherwise, changes the underlying value of a company. In this case, the drastically reduced number of shares is offset by a higher per-share price. As is typical in these situations, ChargePoint made the split to regain compliance with its market's minimum price requirement. Specifically, the New York Stock Exchange stipulates an average of at least $1 per share across a 30-day trading period. The skinny share price is, in many ways, the least of ChargePoint's roadblocks. The company has struggled with declining revenue growth and continuing bottom-line losses. Meanwhile, electric vehicle (EV) sales growth isn't as robust as it was in previous years. Bullish developments Not all the news for ChargePoint was discouraging during the week. It launched its Safeguard Care program, which it describes as a service that "provides end-to-end reliability monitoring of ChargePoint charging stations." This should be reassuring to clients and give the company something of an edge over rivals. Should you buy stock in ChargePoint right now? Before you buy stock in ChargePoint, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and ChargePoint wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why ChargePoint Stock Slumped This Week was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
